Insider Trading activities of Foamix Pharmaceuticals Ltd. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Foamix Pharmaceuticals Ltd. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Foamix Pharmaceuticals Ltd. since year 2005. Table 2 shows the detailed insider transactions of Foamix Pharmaceuticals Ltd. since 2005. The reporting company's ticker symbol is FOMX. The reporting company's CIK number is 1606645.
The total value of stock buying since 2005 is $437,772.
The total value of stock sales since 2005 is $412,755.
The total value of stock option exercises since 2005 is $0.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Foamix Pharmaceuticals Ltd. (FOMX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-12 0 $0 68 $275 0 $0
2018-11 112,200 $437,772 11,156 $45,373 0 $0
2018-10 0 $0 977 $5,675 0 $0
2018-09 0 $0 67 $379 0 $0
2018-08 0 $0 10,953 $62,212 0 $0
2018-07 0 $0 978 $4,987 1,616 $0
2018-06 0 $0 67 $352 0 $0
2018-05 0 $0 6,164 $31,368 0 $0
2018-04 0 $0 978 $4,967 0 $0
2018-03 0 $0 883 $5,408 0 $0
2018-01 0 $0 40,000 $251,759 33,110 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Foamix Pharmaceuticals Ltd. insiders (FOMX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-12-03 Domzalski David (CEO) Sale 68 4.05 275
2018-11-28 Schwartz Aharon Buy 12,200 3.88 47,372
2018-11-27 Schwartz Aharon Buy 50,000 3.92 195,800
2018-11-26 Schwartz Aharon Buy 50,000 3.89 194,600
2018-11-19 Domzalski David (CEO) Sale 5,036 3.90 19,640
2018-11-19 Howard Alvin D (VP Regulatory) Sale 3,375 3.90 13,162
2018-11-08 Domzalski David (CEO) Sale 2,062 4.58 9,443
2018-11-08 Stuart Iain (SVP R&D) Sale 683 4.58 3,128
2018-10-01 Elliott Russell P. (VP Drug Development) Sale 142 5.81 825
2018-10-01 Domzalski David (CEO) Sale 601 5.81 3,491
2018-10-01 Howard Alvin D (VP Regulatory) Sale 234 5.81 1,359
2018-09-04 Domzalski David (CEO) Sale 67 5.67 379
2018-08-08 Domzalski David (CEO) Sale 8,238 5.68 46,791
2018-08-08 Stuart Iain (SVP R&D) Sale 2,715 5.68 15,421
2018-07-13 Hirsch Stanley Option Ex 1,616 .00 0
2018-07-02 Elliott Russell P. (VP Drug Development) Sale 142 5.10 724
2018-07-02 Domzalski David (CEO) Sale 602 5.10 3,070
2018-07-02 Howard Alvin D (VP Regulatory) Sale 234 5.10 1,193
2018-06-01 Domzalski David (CEO) Sale 67 5.26 352
2018-05-13 Hirsch Stanley Sale 6,164 5.09 31,368
2018-04-02 Elliott Russell P. (VP Drug Development) Sale 142 5.08 721
2018-04-02 Domzalski David (CEO) Sale 602 5.08 3,058
2018-04-02 Howard Alvin D (VP Regulatory) Sale 234 5.08 1,188
2018-03-02 Elliott Russell P. (VP Drug Development) Sale 817 6.14 5,016
2018-03-01 Domzalski David (CEO) Sale 66 5.95 392
2018-01-15 Shirvan Mitchell (VP Innovation & Discovery) Option Ex 562 .00 0
2018-01-15 Schuz David (VP IP) Option Ex 562 .00 0
2018-01-15 Hazot Yohan (VP Pharmaceutical Development) Option Ex 562 .00 0
2018-01-15 Hadar Ilan (CFO & Country Manager) Option Ex 562 .00 0
2018-01-15 Eini Meir Option Ex 1,125 .00 0
2018-01-11 Eini Meir Sale 5,000 6.33 31,660
2018-01-10 Eini Meir Sale 5,000 6.04 30,225
2018-01-09 Eini Meir Sale 5,000 6.10 30,520
2018-01-08 Eini Meir Sale 5,000 6.17 30,850
2018-01-05 Eini Meir Sale 5,000 6.58 32,880
2018-01-04 Eini Meir Sale 5,000 6.68 33,410
2018-01-03 Eini Meir Sale 5,000 6.26 31,309
2018-01-02 Eini Meir Sale 5,000 6.18 30,905
2018-01-01 Elliott Russell P. (VP Drug Development) Option Ex 1,372 .00 0
2018-01-01 Domzalski David (CEO) Option Ex 5,948 .00 0
2018-01-01 Shirvan Mitchell (VP Innovation & Discovery) Option Ex 2,745 .00 0
2018-01-01 Schuz David (VP IP) Option Ex 2,745 .00 0
2018-01-01 Hazot Yohan (VP Pharmaceutical Development) Option Ex 4,575 .00 0
2018-01-01 Hadar Ilan (CFO & Country Manager) Option Ex 5,032 .00 0
2018-01-01 Eini Meir Option Ex 5,032 .00 0
2018-01-01 Howard Alvin D (VP Regulatory) Option Ex 2,288 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises of FOMX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Foamix Pharmaceuticals Ltd. (symbol FOMX, CIK number 1606645) see the Securities and Exchange Commission (SEC) website.